ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma

scientific article published in January 2005

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/ANNONC/MDI834
P698PubMed publication ID15888760
P5875ResearchGate publication ID7852083

P2093author name stringS Jelic
N Pavlidis
ESMO Guidelines Task Force
R Stupp
P304page(s)i64-5
P577publication date2005-01-01
P1433published inAnnals of OncologyQ326122
P1476titleESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma
P478volume16 Suppl 1

Reverse relations

cites work (P2860)
Q517085203D conformal radiotherapy and cisplatin for recurrent malignant glioma.
Q42113451A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Q61796646Brown Seaweed 's Cytotoxic Activity against Brain Cancer Cell Lines
Q90334393Curcumin-induced cell death depends on the level of autophagic flux in A172 and U87MG human glioblastoma cells
Q38593139Endocannabinoids and Cancer.
Q42425989FasL gene knock-down therapy enhances the antiglioma immune response
Q27333552Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV
Q37109249Inhibition of glioma growth by minocycline is mediated through endoplasmic reticulum stress-induced apoptosis and autophagic cell death
Q28082580Ion transporters in brain tumors
Q44517700Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution
Q47967307Myo-inositol concentration in MR spectroscopy for differentiating high grade glioma from primary central nervous system lymphoma.
Q37407066Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial
Q37700702Potential regulation of glioma through the induction of apoptosis signaling via Egl-9 family hypoxia-inducible factor 3
Q34584754Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma
Q55463292Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme - Results from a pilot study.
Q35681474S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells
Q48372089Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.
Q28390962Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy
Q36231572The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials
Q64061395The Volume-Regulated Anion Channel in Glioblastoma
Q55501535The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis.
Q54946129UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice.
Q30572906WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration

Search more.